Business
Board Change
Board Change.
About this update from Shield Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 6956Q Shield Therapeutics PLC 14 September 2017 \n\nShield Therapeutics plc\n(\"Shield\" or the \"Group\")\n \nBoard Change\n \nLondon, UK, 14th September 2017: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that Joanne Estell, has resigned her Board position and as Chief Financial Officer (\"CFO\") and Company Secretary to pursue other business interests outside the healthcare sector. \n \nA search process for a new CFO has commenced and the Board has appointed Dr Karl Keegan as interim Chief Financial Officer with immediate effect. Dr Keegan has a background of senior financial positions in the specialty pharmaceutical sector and in his previous capacity as Director of Corporate Development, has worked closely with Joanne, Shield's Leadership Team and the Board on all aspects of the Group's operations and strategy development. They will work together through to the end of October to deliver a smooth and effective transition.\n \nDr Keegan has previously held CFO positions at Pharma Group NV, and Minster Pharmaceuticals plc, as well as managerial roles at SmithKline Beecham (now GlaxoSmithKline). Dr Keegan also spent over 12 years as a sell-side analyst at UBS, Bank of America, Canaccord, and Dresdner Kleinworth Benson.\n \nCarl Sterritt, Founder and Chief Executive Officer of Shield Therapeutics, said: \"On behalf of the Board, I thank Joanne for her contributions to the growth of Shield as a publicly listed company, particularly her role in the recent financing. We are fortunate and pleased to be able to appoint Karl as interim CFO. He is a well-qualified and suitably sector-experienced internal successor to Joanne and we look forward to working with Karl on Shield's continued success. We look forward to updating investors on recent progress within the business on 20 September when we publish our interim results.\"\n \n- Ends -\n \nFor further information please contact:\n \nShield Therapeutics plc &...